Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

Phase 2/3 Completed 238 enrolled University of Leicester GlaxoSmithKline · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.

Timeline

Start: 2020-09-07
Primary completion: 2024-06-21
Completion: 2024-06-21

Outcome

Missed primary endpoint

paper hazard ratio, 0.96; 95% confidence interval [CI], 0.70 to 1.32; P=0.811 PMID 40305842 ↗

paper had no benefit in risk of time to readmission or death following treatment with mepolizumab for 48 weeks. PMID 40305842 ↗

Publications

Flynn CA, McAuley HJC, Elneima O, Aung HWW, Ibrahim W, Ward TJC, Bourne M, Thornton TD, Mistry V, Gilbert HR, Waheed G, Wright AKA, Evans RA, Steiner MC, Brookes CL, Brightling CE, Greening NJ. Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization. NEJM Evid. 2025 Jun;4(6):EVIDoa2500012. doi: 10.1056/EVIDoa2500012. Epub 2025 Apr 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mepolizumab	Monoclonal antibody	100 mg	Subcutaneous